Brief: Emergent BioSolutions Q2 Revenue USD 140.9 Million

Emergent BioSolutions

06/08/2025 21:15

Overview

Emergent Q2 revenue of $140.9 mln missed analyst expectations, exceeded Co's guidance by $21 mln

Adjusted EBITDA rose 382% to $28.5 mln, beating analyst estimates

Company raised low end/midpoint of full-year 2025 profitability guidance

Outlook

Emergent raises full-year 2025 revenue guidance to $765-$835 mln

Company revises 2025 net income forecast to $40-$65 mln

Company anticipates full-year 2025 adjusted EBITDA of $175-$200 mln

Result Drivers

NALAXONE SALES DECLINE - Revenues from NARCAN Nasal Spray fell 44% due to unfavorable price and volume mix

ANTHRAX MCM SALES TIMING - Anthrax MCM revenues decreased 70% due to timing of sales related to CYFENDUS

SMALLPOX MCM SALES INCREASE - Smallpox MCM revenues rose 127% driven by higher VIGIV CNJ-016 sales

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$140.90 mln
$146.40 mln (3 Analysts)
Q2 Adjusted EPS
$0.16
Q2 Adjusted Net Income
Beat
$8.60 mln
-$27.60 mln (2 Analysts)
Q2 Net Income
-$12 mln
Q2 Adjusted EBITDA
Beat
$28.50 mln
-$10.30 mln (1 Analyst)
Q2 Gross Margin
36.0%
Q2 Adjusted Gross Margin
49.0%


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 54.8% above its August 5 closing price of $6.10

Press Release: ID:nGNX3qB8bL

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)